Cargando…

New TMA (4,6,4′-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease

A series of new-generation TMA (4,6,4′-trimethyl angelicin) analogues was projected and synthetized in order to ameliorate anti-inflammatory activity, with reduced or absent toxicity. Since the NF-κB transcription factor (TF) plays a critical role in the expression of IL-8 (Interluekin 8), a typical...

Descripción completa

Detalles Bibliográficos
Autores principales: Tupini, Chiara, Chilin, Adriana, Rossi, Alice, De Fino, Ida, Bragonzi, Alessandra, D’Aversa, Elisabetta, Cosenza, Lucia Carmela, Vaccarin, Christian, Sacchetti, Gianni, Borgatti, Monica, Tamanini, Anna, Dechecchi, Maria Cristina, Sanvito, Francesca, Gambari, Roberto, Cabrini, Giulio, Lampronti, Ilaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699093/
https://www.ncbi.nlm.nih.gov/pubmed/36430961
http://dx.doi.org/10.3390/ijms232214483
_version_ 1784838985999187968
author Tupini, Chiara
Chilin, Adriana
Rossi, Alice
De Fino, Ida
Bragonzi, Alessandra
D’Aversa, Elisabetta
Cosenza, Lucia Carmela
Vaccarin, Christian
Sacchetti, Gianni
Borgatti, Monica
Tamanini, Anna
Dechecchi, Maria Cristina
Sanvito, Francesca
Gambari, Roberto
Cabrini, Giulio
Lampronti, Ilaria
author_facet Tupini, Chiara
Chilin, Adriana
Rossi, Alice
De Fino, Ida
Bragonzi, Alessandra
D’Aversa, Elisabetta
Cosenza, Lucia Carmela
Vaccarin, Christian
Sacchetti, Gianni
Borgatti, Monica
Tamanini, Anna
Dechecchi, Maria Cristina
Sanvito, Francesca
Gambari, Roberto
Cabrini, Giulio
Lampronti, Ilaria
author_sort Tupini, Chiara
collection PubMed
description A series of new-generation TMA (4,6,4′-trimethyl angelicin) analogues was projected and synthetized in order to ameliorate anti-inflammatory activity, with reduced or absent toxicity. Since the NF-κB transcription factor (TF) plays a critical role in the expression of IL-8 (Interluekin 8), a typical marker of lung inflammation in Cystic Fibrosis (CF), the use of agents able to interfere with the NF-κB pathway represents an interesting therapeutic strategy. Through preliminary EMSA experiments, we identified several new TMA derivatives able to inhibit the NF-κB/DNA complex. The selected active molecules were then analyzed to evaluate the anti-inflammatory effect using both Pseudomonas aeruginosa (PAO1) infection and TNF-alpha stimulus on the CF IB3-1 cell line. It was demonstrated that mainly two TMA analogues, GY971a mesylate salt (6-p-minophenyl-4,4′-dimethyl-angelicin) and GY964 (4-phenyl-6,4′-dimethyl-angelicin), were able to decrease the IL-8 gene expression. At the same time, these molecules were found to have no pro-apoptotic, mutagenic and phototoxic effects, facilitating our decision to test the efficacy in vivo by using a mouse model of acute P. aeruginosa lung infection. The anti-inflammatory effect of GY971a was confirmed in vivo; this derivative was able to deeply decrease the total number of inflammatory cells, the neutrophil count and the cytokine/chemokine profile in the P. aeruginosa acute infection model, without evident toxicity. Considering all the obtained and reported in vitro and in vivo pre-clinical results, GY971a seems to have interesting anti-inflammatory effects, modulating the NF-κB pathway, as well as the starting lead compound TMA, but without side effects.
format Online
Article
Text
id pubmed-9699093
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96990932022-11-26 New TMA (4,6,4′-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease Tupini, Chiara Chilin, Adriana Rossi, Alice De Fino, Ida Bragonzi, Alessandra D’Aversa, Elisabetta Cosenza, Lucia Carmela Vaccarin, Christian Sacchetti, Gianni Borgatti, Monica Tamanini, Anna Dechecchi, Maria Cristina Sanvito, Francesca Gambari, Roberto Cabrini, Giulio Lampronti, Ilaria Int J Mol Sci Article A series of new-generation TMA (4,6,4′-trimethyl angelicin) analogues was projected and synthetized in order to ameliorate anti-inflammatory activity, with reduced or absent toxicity. Since the NF-κB transcription factor (TF) plays a critical role in the expression of IL-8 (Interluekin 8), a typical marker of lung inflammation in Cystic Fibrosis (CF), the use of agents able to interfere with the NF-κB pathway represents an interesting therapeutic strategy. Through preliminary EMSA experiments, we identified several new TMA derivatives able to inhibit the NF-κB/DNA complex. The selected active molecules were then analyzed to evaluate the anti-inflammatory effect using both Pseudomonas aeruginosa (PAO1) infection and TNF-alpha stimulus on the CF IB3-1 cell line. It was demonstrated that mainly two TMA analogues, GY971a mesylate salt (6-p-minophenyl-4,4′-dimethyl-angelicin) and GY964 (4-phenyl-6,4′-dimethyl-angelicin), were able to decrease the IL-8 gene expression. At the same time, these molecules were found to have no pro-apoptotic, mutagenic and phototoxic effects, facilitating our decision to test the efficacy in vivo by using a mouse model of acute P. aeruginosa lung infection. The anti-inflammatory effect of GY971a was confirmed in vivo; this derivative was able to deeply decrease the total number of inflammatory cells, the neutrophil count and the cytokine/chemokine profile in the P. aeruginosa acute infection model, without evident toxicity. Considering all the obtained and reported in vitro and in vivo pre-clinical results, GY971a seems to have interesting anti-inflammatory effects, modulating the NF-κB pathway, as well as the starting lead compound TMA, but without side effects. MDPI 2022-11-21 /pmc/articles/PMC9699093/ /pubmed/36430961 http://dx.doi.org/10.3390/ijms232214483 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tupini, Chiara
Chilin, Adriana
Rossi, Alice
De Fino, Ida
Bragonzi, Alessandra
D’Aversa, Elisabetta
Cosenza, Lucia Carmela
Vaccarin, Christian
Sacchetti, Gianni
Borgatti, Monica
Tamanini, Anna
Dechecchi, Maria Cristina
Sanvito, Francesca
Gambari, Roberto
Cabrini, Giulio
Lampronti, Ilaria
New TMA (4,6,4′-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease
title New TMA (4,6,4′-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease
title_full New TMA (4,6,4′-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease
title_fullStr New TMA (4,6,4′-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease
title_full_unstemmed New TMA (4,6,4′-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease
title_short New TMA (4,6,4′-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease
title_sort new tma (4,6,4′-trimethyl angelicin) analogues as anti-inflammatory agents in the treatment of cystic fibrosis lung disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699093/
https://www.ncbi.nlm.nih.gov/pubmed/36430961
http://dx.doi.org/10.3390/ijms232214483
work_keys_str_mv AT tupinichiara newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT chilinadriana newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT rossialice newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT definoida newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT bragonzialessandra newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT daversaelisabetta newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT cosenzaluciacarmela newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT vaccarinchristian newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT sacchettigianni newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT borgattimonica newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT tamaninianna newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT dechecchimariacristina newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT sanvitofrancesca newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT gambariroberto newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT cabrinigiulio newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease
AT lamprontiilaria newtma464trimethylangelicinanaloguesasantiinflammatoryagentsinthetreatmentofcysticfibrosislungdisease